A Randomized Non-Comparative Phase II Study of Nivolumab or Nivolumab/BMS-986205 alone or combined with Intravesical BCG in Patients with BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer

Brief description of study

If you have been diagnosed with BCG unresponsive, high-risk, non-muscle invasive bladder cancer, you may qualify for this study. The main purpose of the study is to assess the effectiveness (how well the drug works), safety, and tolerability of the investigational drugs called nivolumab or nivolumab with ID01 Inhibitor (BMS-986205) alone or combined with BCG (Bacille Calmette Guerin) in participants with BCG unresponsive, high-risk, non-muscle invasive bladder cancer.


Clinical Study Identifier: s18-00281
ClinicalTrials.gov Identifier: NCT03519256
Principal Investigator: Arjun Vasant Balar
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.